Regenxbio (RGNX) Asset Writedowns and Impairment (2024)
Regenxbio (RGNX) posted quarterly Asset Writedowns and Impairment of $700000.0 for Q1 2024, up 34900.0% quarter-over-quarter from $2000.0 in Q4 2014.
Powered by 
Analysis
Regenxbio (RGNX) Asset Writedowns and Impairment (2024) Analysis & Trends
Regenxbio's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $700000.0 for Q1 2024.
- In Q1 2024, Asset Writedowns and Impairment changed N/A year-over-year to $700000.0; the TTM figure through Dec 2024 stood at $700000.0 (changed N/A YoY), while the FY2024 annual figure was $2.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q1 2024 stood at $700000.0, up from $2000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $700000.0 in Q1 2024, with the low at $700000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Regenxbio | 472.74 Mn | 367.22 Mn | - |